中国肝硬化腹水管理及相关并发症指南

StephenW

Hepatology International

January 2019, Volume 13, Issue 1, pp 1–21 | Cite as
Chinese guidelines on the management of ascites and its related complications in cirrhosis

    Authors
    Authors and affiliations

    Chinese Society of Hepatology, Chinese Medical AssociationXiaoyuan XuEmail authorZhongping DuanHuiguo DingWengang LiJidong JiaLai WeiEnqiang LinghuHui Zhuang

    Chinese Society of Hepatology, Chinese Medical Association
    Xiaoyuan Xu
        1Email author
    Zhongping Duan
        2
    Huiguo Ding
        3
    Wengang Li
        4
    Jidong Jia
        5
    Lai Wei
        6
    Enqiang Linghu
        7
    Hui Zhuang
        8

    1.Department of Infectious DiseasesPeking University First HospitalBeijingChina
    2.Artificial Liver CenterBeijing You-An Hospital, Capital Medical UniversityBeijingChina
    3.Center for Hepatology and Gastroenterology, Beijing You-An HospitalCapital Medical UniversityBeijingChina
    4.Liver Tumor Diagnosis, Treatment and Research CenterBeijingChina
    5.Liver Research Center, Beijing Friendship HospitalCapital Medical UniversityBeijingChina
    6.Institute of HepatologyPeking University People’s HospitalBeijingChina
    7.Department of GastroenterologyChinese PLA General HospitalBeijingChina
    8.Department of Pathogen BiologyPeking University Health Science CenterBeijingChina

Guidelines
First Online: 18 January 2019

    313 Downloads

Abstract

The Chinese Society of Hepatology developed the current guidelines for the Management of Ascites and Its Related Complications in Cirrhosis based on the published evidences and the panelists’ consensus. The guidelines provided recommendations for the diagnosis and management of cirrhotic ascites emphasizing a step-wise approach with the first-, second-, and third-line therapy. For refractory ascites, vasoconstrictors and albumin are recommended for splanchnic vasodilation and selective vasopressin (V2) receptor antagonists for moderate-to-severe hyponatremia. For spontaneous bacterial peritonitis, empirical anti-infection treatment was recommended based on the local microbiological examination of community- or hospital-acquired infections. For hepatorenal syndrome, the administration of vasopressor terlipressin and albumin is recommended.
Keywords
Liver cirrhosis Ascites SBP Hepatorenal syndrome Diagnosis Therapy Guidelines

StephenW

国际肝病学

2019年1月，第13卷，第1期，第1-21页|引用为
中国肝硬化腹水管理及相关并发症指南

    作者
    作者和附属机构

    中华医学会中华医学会徐晓媛作者：中国段惠国丁文刚李继东贾来魏恩强令狐慧壮

    中华医学会中华肝脏病学会
    徐晓媛
        1Email作者
    中平段
        2
    丁惠国
        3
    李文刚
        4
    冀东佳
        五
    赖伟
        6
    恩强令狐
        7
    惠庄
        8

    1.传染病科北京大学第一医院北京中国
    2.人工肝中心首都医科大学北京友安医院北京中国
    3.北京右安医院首都医科大学肝病学与胃肠病学中心北京中国
    4.Liver肿瘤诊断，治疗和研究中心北京中国
    5.北京友谊医院肝病研究中心，首都医科大学，北京，中国
    6.北京中医药大学人民医院肝病研究所
    7.中国人民解放军总医院消化内科，北京中国
    8.病原生物学系北京大学健康科学中心北京中国

方针
首次在线：2019年1月18日

    313次下载

抽象

根据已发表的证据和小组成员的共识，中国肝病学会制定了目前关于肝硬化腹水及其相关并发症的指南。该指南为肝硬化腹水的诊断和治疗提供了建议，强调了一线，二线和三线治疗的逐步方法。对于难治性腹水，血管收缩剂和白蛋白被推荐用于内脏血管舒张和选择性加压素（V2）受体拮抗剂用于中度至重度低钠血症。对于自发性细菌性腹膜炎，建议根据社区或医院获得性感染的局部微生物学检查进行经验性抗感染治疗。对于肝肾综合征，建议给予血管加压剂特利加压素和白蛋白。
关键词
肝硬化腹水SBP肝肾综合征诊断治疗指南

StephenW

https://link.springer.com/articl ... aign=toc_12072_13_1